Recent research reveals that autism spectrum disorder (ASD) now affects an estimated one in 40 children in the United States, a significant jump from the previous estimate of one in 59 by the Centers for Disease Control and Prevention (CDC). With this rising prevalence, the quest for effective treatments has become more urgent than ever. Emerging evidence suggests that medical cannabis may offer potential benefits for individuals with ASD and their families, providing a new avenue for alleviating symptoms such as sleep disturbances, concentration difficulties, and anger outbursts.
Medical Cannabis and ASD: Advocating for Change
Since 2014, the grassroots organization Mothers Advocating Medical Marijuana for Autism (MAMMA) has been at the forefront of advocating for better access to comprehensive medical cannabis treatments for autism. Their efforts have led to significant milestones, such as the recent passage of a law in Colorado on World Autism Day, April 2, authorizing medical cannabis use for treating autism. This development places Colorado among the 15 U.S. states and territories recognized by MAMMA as supportive of autism-related cannabis treatments.
Cannabidivarin (CBDV)
One of the most promising compounds derived from cannabis for treating autism symptoms is cannabidivarin (CBDV). Discovered in 1969, CBDV is a non-psychoactive component of cannabis that has been explored for its potential in epilepsy treatment. Recent studies suggest that CBDV may also hold promise for alleviating symptoms of ASD.
Real-Life Experience Study
A recent observational study conducted by Israeli researchers examined the effects of CBDV on children with ASD. The study's findings are encouraging: over 80% of parents reported a "significant or moderate improvement in the child global assessment." The most common side effect reported was restlessness, but CBDV also appeared to enhance sleep and concentration. At the beginning of the study, less than 4% of participants reported good sleep, and none reported good concentration. During the treatment period, 25% of the participants experienced improved sleep, and 14% showed better concentration.
First-Ever Clinical Trial of CBDV for Autism
While the Israeli study provides valuable insights, its observational nature means its findings carry less scientific weight compared to controlled trials. To address this, a new clinical trial funded by a $1.3 million grant from the Department of Defense aims to provide more conclusive answers regarding the benefits of CBDV for ASD. Leading the study is Dr. Eric Hollander, a professor of psychiatry and behavioral sciences at Montefiore Medical Center in New York City.
The trial will involve 100 children aged five to 18 who will receive either CBDV or a placebo twice daily for 12 weeks. Supported by GW Pharmaceuticals, a UK-based company specializing in cannabis-derived medications, the study will primarily assess the effect of CBDV on irritability, a common symptom of ASD. Additionally, the trial will examine its impact on repetitive behaviors, social withdrawal, and overall quality of life.
Dr. Hollander emphasized the importance of addressing the behavioral challenges faced by individuals with ASD and the burden on both the children and their families. "There are few medications available to treat ASD, and current treatment options have substantial side effects. We are hoping that CBDV will prove to be an effective method for managing disruptive and impulsive behaviors in patients with ASD, while also targeting the underlying mechanisms in the brain that give rise to these behaviors," he stated in a news release from Montefiore.
A Hopeful Future
As research into the potential benefits of cannabis for ASD continues, there is hope that compounds like CBDV could offer new, effective treatment options for individuals with autism. At CannaLnx, we are committed to supporting this research and advocating for improved access to high-quality cannabis products. We've partnered with reputable CBD producers like Bloom Hemp and Pin High CBD to ensure our members have access to the best products available. Links to their sites can be found under the "Offerings" tab in the CannaLnx header, and all CannaLnx member patients receive special discounts at these CBD partner companies.
The future of cannabis in treating ASD looks promising, and with continued research and advocacy, we hope to see more effective and safe treatment options available for those in need.
